Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of the firm’s stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $9.34, for a total transaction of $207,553.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Adrian Haigh also recently made the following trade(s):

• On Monday, April 22nd, Adrian Haigh sold 22,223 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.32, for a total transaction of $207,118.36.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.91, for a total transaction of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total value of $228,886.60.

Fennec Pharmaceuticals Trading Down 1.5 %

Shares of FENC opened at $9.24 on Wednesday. The firm has a market cap of $250.40 million, a PE ratio of -15.15 and a beta of 0.38. Fennec Pharmaceuticals Inc has a 12 month low of $6.30 and a 12 month high of $11.92. The stock has a fifty day moving average price of $10.05 and a 200-day moving average price of $9.42.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The business had revenue of $9.74 million during the quarter, compared to the consensus estimate of $9.47 million. As a group, research analysts forecast that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on FENC shares. HC Wainwright boosted their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, April 4th. Craig Hallum increased their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Finally, Wedbush restated an “outperform” rating and issued a $16.00 price target on shares of Fennec Pharmaceuticals in a report on Monday, March 18th.

Institutional Trading of Fennec Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its stake in Fennec Pharmaceuticals by 107.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after purchasing an additional 1,578 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Fennec Pharmaceuticals during the third quarter valued at $50,000. Jump Financial LLC acquired a new position in shares of Fennec Pharmaceuticals in the 4th quarter valued at $158,000. Eudaimonia Advisors LLC raised its stake in Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after acquiring an additional 15,556 shares during the last quarter. Finally, Hartford Financial Management Inc. lifted its position in Fennec Pharmaceuticals by 4.4% during the 4th quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock worth $531,000 after acquiring an additional 2,000 shares during the period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.